2Firsts, September 8th - According to a Reuters report on September 8, the U.S. Food and Drug Administration (FDA) will launch a pilot program to accelerate the review of nicotine pouch products from Philip Morris International, Altria, British American Tobacco’s Reynolds American, and Turning Point Brands, with the goal of completing the process by December this year.
Previously, approval for such products often took years. The move comes under pressure from the Trump administration and is aimed at improving efficiency. Nicotine pouches are the fastest-growing category of smoking alternatives in the United States. Although considered lower risk than traditional tobacco, they continue to raise concerns about youth uptake. Philip Morris currently leads the U.S. market with its Zyn brand, while other companies are scrambling to catch up.
The key takeaways from the article are as follows:
● Regulatory Action: The FDA will launch a pilot program on Monday to accelerate the review of nicotine pouch products from four companies—Philip Morris International (PMI), Altria, Reynolds American (owned by British American Tobacco, BAT), and Turning Point Brands—with the goal of completing reviews by December 2025.
● Motivation and Pressure: Meeting transcripts show that the FDA has been under pressure from leadership, including the White House, to speed up reviews. The Department of Health and Human Services (HHS) and the White House did not immediately respond to requests for comment.
● Past Delays: Historically, nicotine pouch reviews have taken years. In January 2025, the FDA authorized 20 pouch products from PMI’s Zyn brand, more than five years after the company’s initial submission.
● Participation and Market Status: Some products in the pilot are not yet on the market and await FDA clearance (e.g., Zyn Ultra). Others are already being sold without authorization; FDA approval would remove legal uncertainty and reduce the risk of potential enforcement.
● Brands/Products Included: PMI’s Zyn Ultra; Altria’s on! / on! Plus; Reynolds’ Velo mini; Turning Point Brands’ Fre and Alp (the latter co-owned by former Fox News host Tucker Carlson).
● Review Framework: The pilot will feature streamlined and reduced reviews, more frequent communication between FDA staff and applicants, and expedited clearance. Reviews will focus on core information only: scientific essentials for nicotine pouch evaluation, product characterization, manufacturing consistency and stability, and abuse-liability data.
● Industry Responses:
○ PMI: Called a faster review “a step in the right direction,” though the company said it was not aware of such an initiative.
○ Altria: Described the approach as encouraging and a positive step for harm reduction.
○ Turning Point Brands: Said the streamlined path reflects the administration’s commitment to efficiency, effectiveness, and transparency.
○ Reynolds: Declined to comment.
● Market Context: Nicotine pouches are the fastest-growing category of smoking alternatives in the U.S. They are widely viewed as lower-risk because they contain no tobacco and involve no inhalation, but critics warn of risks such as youth appeal. Yolonda Richardson, CEO of the Campaign for Tobacco-Free Kids (CTFK), stressed that “there should be no shortcuts” in protecting children’s health. An FDA official noted that current evidence does not show significant uptake among youth.
● Competition and Growth: PMI leads the U.S. market with Zyn, which has posted quarterly shipment growth of 40%–80% since January 2023. BAT and Altria are scrambling to catch up.
● Politics and Lobbying: Tobacco companies have lobbied Trump and other key officials this year for a faster and clearer approval process. Federal Election Commission (FEC) filings show that Reynolds American donated $10 million to the Trump-aligned super PAC Make America Great Again Inc.
